Study wrapper · #910
Effect of short-term tirzepatide treatment on mean platelet volume in patients with obesity: a retrospective controlled study.
Demircan F, Ozozan OV, Gozel N BMC endocrine disorders. 2026.
DOI: 10.1186/s12902-026-02422-8PubMed: 42464179
Editor's note
Tirzepatide is the direct subject, and the observed drop in mean platelet volume is a plausible inflammation-related signal. The authors appropriately frame the results as hypothesis-generating given the retrospective design, small size, short follow-up, and absence of direct platelet-function biomarkers. Not a basis for firm claims.
Plain-language abstract
In a small retrospective study, two months of tirzepatide was associated with reductions in BMI and mean platelet volume compared with untreated controls in patients with obesity.
Related coverage
Weak / none
Cost-effectiveness of tirzepatide versus semaglutide for patients with obesity or overweight in the US: evidence from the SURMOUNT-5 head-to-head phase-3 trial.
Journal of medical economicsn=——2026
Mixed
Sleeve gastrectomy versus tirzepatide to improve survival among patients with stage 5 CKD: A Markov decision analysis.
American journal of surgeryn=——2026
Mixed
Development and validation of a multiplexed LC-HRMS method for nine GLP-1 receptor agonists and its pharmaceutical application.
Journal of chromatography. An=——2026